Background. Patients with ductal carcinoma in situ (DCIS) are at increased risk for developing contralateral breast cancer (CBC). Consequently, more women with DCIS are electing to undergo contralateral prophylactic mastectomy (CPM). We evaluated factors associated with CPM in patients with DCIS who underwent genetic counseling for BRCA testing. Methods. This retrospective study involved 165 women with DCIS referred for genetic counseling between 2003 and 2011. Patient characteristics were age, marital and educational status, tumor markers, nuclear grade, family history of breast cancer (BC) and ovarian cancer (OC), race, Ashkenazi Jewish ancestry, and BRCA results. Univariate and multivariate logistic regression analyses were used to determine predictive factors associated with CPM election. Results. Of 165 patients, 44 (27 %) underwent CPM. Patients \45 years of age were more likely to elect CPM (p = 0.0098). A BRCA? mutation was found in 17 patients (10.3 %), and BRCA? women were more likely to elect CPM than BRCA or untested women (p = 0.0001). Patients who had a family history of OC (57.7 %) were more likely to choose CPM than those with no family history (p = 0.0004). Younger age, BRCA?, and an OC family history remained significant in the multivariate model (p \ 0.008). Conclusion. The CPM rate among patients with DCIS who undergo genetic counseling is high. Factors associated with increased likelihood of CPM among this group were age, BRCA?, and a family history of OC. Further studies are needed to evaluate patients' perceptions of CBC risk and their role in the likelihood of CPM choice.
family history remained significant in the multivariate model (p \ 0.008). Conclusion. The CPM rate among patients with DCIS who undergo genetic counseling is high. Factors associated with increased likelihood of CPM among this group were age, BRCA?, and a family history of OC. Further studies are needed to evaluate patients' perceptions of CBC risk and their role in the likelihood of CPM choice.
Ductal carcinoma in situ (DCIS) increased 7.2-fold between 1980 and 2001 as a result of the increased use of screening mammography, 1 and the detection rate continued to increase during the last decade. 2 Although DCIS is not immediately life-threatening, patients with DCIS in one breast are at increased risk for developing contralateral breast cancer (CBC). 3 The risk for developing either invasive cancer or DCIS in the contralateral breast is 0.6 % per year. 1, 2 To reduce CBC risk, an increasing number of women with DCIS are electing to undergo contralateral prophylactic mastectomy (CPM). 1, 2, 4 One of the largest risk factors for breast cancer (BC) is hereditary predisposition. The BRCA1 and BRCA2 gene mutations have been shown to indicate a higher susceptibility to develop BC. Individuals who carry one of these mutations have a 43-84 % risk of developing BC, and up to a 65 % risk for CBC. 5, 6 Prospective studies of BRCA mutation carriers have shown that bilateral prophylactic mastectomy (BPM) reduces BC risk by more than 90 %. 7 It has been reported that among BRCA mutation carriers, up to 65 % of women with BC and 15-60 % of unaffected women undergo risk-reduction breast surgeries. [8] [9] [10] [11] The election to undergo prophylactic surgery is dependent upon several factors such as age, the desire to have children, and family history. [17] [18] [19] [20] The prevalence of BRCA mutations in patients with DCIS has been reported. 1, 12 Our previous study 1 indicated a 27 % prevalence of deleterious BRCA mutations among 118 patients with DCIS who were referred for genetic counseling. This study indicated that women who had DCIS and a family history of ovarian cancer (OC) had higher rates of BRCA positivity. Hwang et al. 12 retrospectively reviewed 129 BRCA-positive and 269 BRCAnegative women undergoing genetic testing, and found that 37 % of BRCA carriers had DCIS. Several previous studies assessed the prevalence of BRCA1 and BRCA2 mutations among women with DCIS and reported rates between 3.3 and 13 %. 1, 13, 14 The frequency and patterns regarding CPM choice among patients with DCIS and BRCA mutations have not been well reported. Although several retrospective studies have examined the increasing rate of CPM among patients with DCIS, these studies did not examine variables such as family history, BRCA mutation status, or tumor characteristics and their influence for CPM. 2 The aim of this study was to determine the rate of CPM election and further identify predictive factors for CPM election among patients with DCIS and who were referred for genetic counseling and followed in our high-risk BC and OC clinics.
METHODS

Patient Selection and Data
Between 2003 and 2011, 165 women who were diagnosed with DCIS were referred for genetic counseling and were invited to participate in a prospective registry study that was approved by the Internal Review Board at The University of Texas MD Anderson Cancer Center (MD Anderson). The criteria used to refer patients to genetic counseling were based on the National Comprehensive Cancer Network guidelines. 15 . We excluded patients who had micro-invasion, bilateral DCIS, OC, or a genetic test result indicating a BRCA1 or BRCA2 variant of uncertain significance.
Diagnoses were made based on pathologic evaluation by dedicated breast pathologists at MD Anderson. All patients underwent genetic counseling that included a detailed review of family history. Those who proceeded with genetic testing underwent comprehensive BRCA 1 and BRCA 2 gene sequencing and, in some, the BRACAnalysis Large Rearrangement Test when indicated and when patient agreed to testing. Patients' demographic and clinical characteristics were obtained from the medical record. The variables considered in our analysis were age at the time of diagnosis, race, ethnicity (Ashkenazi Jewish [AJ], or non-AJ ancestry), marital status, educational level completed, family history of BC and/or OC in at least one first-degree relative, total number of relatives who had had BC and/or OC, and, if available, patients' BRCA1 and BRCA2 genetic test results, tumor nuclear grade (as defined by the modified nuclear grade system), estrogen receptor (ER), and progesterone receptor (PR) status [as determined by immunohistochemical analysis].
Statistical Analysis and Outcome Measures
Patients' demographic and clinical characteristics were compared between the two groups and defined according to CPM status (patients who did and did not elect to undergo CPM). Univariate analyses were performed to test the significance of each variable in relation to whether a patient had undergone CPM; Chi-square tests were used for categorical variables, and t tests/analysis of variance or the counterparts of the non-parametric approaches (Wilcoxon rank sum or Kruskal-Wallis tests) were used for continuous variables. 16 Logistic regression analyses were used to assess the multivariate relationship between patient demographics and clinical characteristics and the probability of electing CPM. 17 A logistic regression model was obtained by first including an initial set of candidate predictor variables for which p values (B0.05) had been obtained in the univariate analysis. A stepwise backward elimination was then performed using p B 0.05 for the significance level of the Wald Chi-square for an effect to stay in the model.
RESULTS
Patient characteristics are shown in Table 1 . Of the 165 patients with DCIS who were included in the analysis, 44 (27 %) underwent CPM. Seventeen (10.3 %) of 165 patients were found to have a deleterious BRCA mutation, 91 (55 %) did not have a BRCA mutation, and 57 (35 %) did not undergo genetic testing. CPM was elected in 12 (71 %) of the 17 patients who tested positive for a BRCA mutation, 23 (25 %) of the patients who tested negative, and 9 (16 %) of the 57 patients who did not undergo genetic testing. Eight patients did not undergo testing because the test was cancelled/insurance restrictions, 3 were not interested/declined testing, 14 did not meet the testing criteria, 24 were not seen, 2 indicated other family members will undergo testing, 1 did not show, and 5 did not test for unknown reasons. Rates of CPM by BRCA status are illustrated in Table 2 . (Table 3 ) demonstrated that BRCApositive patients were more likely to choose CPM than BRCA-negative and untested patients (p = 0.0001). Younger (B45 years of age) patients were more likely than older patients to choose CPM (p = 0.0098). When analyzed by family (first-degree relative) history of BC, the difference was not statistically significant (p = 0.221). However, patients with a family history of OC were more CPM contralateral prophylactic mastectomy likely to choose CPM than patients without an OC family history (p = 0.0004).
The multivariate logistic regression model revealed an association between patient characteristics and CPM (Table 4 ). Age at diagnosis and having one or more family members with OC and positive BRCA mutation status remained independent significant predictors of having elected CPM. More specifically, younger patients (median of 45 years of age or younger) were more likely than older patients to choose CPM [odds ratio (OR) 3.07; 95 % confidence interval (CI) 1.33-7.09; p = 0.0085]. Patients with relatives with OC were more likely to undergo CPM (OR 4.34; 95 % CI 1.644-11.46; p = 0.0030). Results of BRCA genetic testing were significantly associated with the probability of having chosen to have CPM (p = 0.0041). Specifically, patients with positive BRCA results were more likely to undergo CPM than those who were not tested (OR 8.64; 95 % CI 2.27-32.82; p = 0.0009) or those with negative test results (OR 6.57; 95 % CI 1.94-22.20; p = 0.0024). Patients with negative BRCA results were more likely to undergo CPM than those who were not tested (OR 1.32; 95 % CI 0.53-3.26). However, the difference in CPM rates between the two groups was only marginally significant (p = 0.0609).
The final multivariate logistic regression model revealed an association between patient characteristics and CPM among patients who were BRCA-negative (Table 5 ). Age at diagnosis and having one or more family members with OC remained independent significant predictors of having elected CPM among patients who tested negative for a BRCA mutation. The regression showed a marginally significant trend that revealed younger patients (median of 45 years of age or younger) were more likely than older patients to have chosen CPM ( 
DISCUSSION
This study revealed a 27 % CPM rate among patients with DCIS, supporting previous work demonstrating the increasing rate of CPM among patients with DCIS. 2 Our multivariate regression analysis revealed that age of 45 years or younger, BRCA positivity, and having one or more relatives with OC independently predicted the decision to undergo CPM. To our knowledge, our study is the first to report rates of CPM among patients with DCIS in light of family history and genetic test results. Few studies have examined the rate of CPM among patients with DCIS; the first to do so by Tuttle and associates analyzed the initial treatment of patients with unilateral DCIS to determine the CPM rate between 1998 and 2005. 2 A 13.5 % CPM rate was revealed among patients who had a mastectomy on the affected side; among all surgically-treated patients, the rate had increased by 148 % between 1998 and 2005. However, the study populations were different. The Tuttle population was analyzed using the Surveillance Epidemiology and End Results database, which allowed for a more population-based approach. Our study included patients who were analyzed based upon referral for genetic counseling and genetic testing.
It has been shown that age plays a role in the decision to pursue prophylactic mastectomy. Our data show that OR odds ratio, CI confidence interval, Pr probability younger DCIS patients are more likely than older patients to elect prophylactic mastectomies. Tuttle's findings also show that DCIS patients younger than 40 years were significantly associated with increased rates of CPM in their cohort. 2 Moreover, Heemskerk-Gerritsen et al. 18 found that prophylactic mastectomy was more prevalent among younger affected (with a history of BC) and/or unaffected women between 37 and 44 years of age. 18 Younger patients especially may benefit from CPM because of their potentially longer lifespan and increased risk for a subsequent BC.
It is also crucial to acknowledge and address the impact of genetic test results on patients' psychological adjustment. Receiving a positive genetic test result is an anxietyprovoking event that elicits psychological distress. Electing CPM can reduce anxiety and constant worry for certain patients. 19 Therefore, patients' perception of future (BC) risk and the psychosocial implications a positive genetic test result can trigger need to be addressed appropriately with care providers.
It has been well established that BPM in BRCA mutation carriers reduces BC risk by 90 %. 7, 9, 21, 23 In a prospective study, Meijers-Heijbor et al. 20 evaluated the incidence of BC among 139 BRCA1 and BRCA2 mutation carriers who elected to undergo either BPM or close surveillance only. During an average follow-up interval of 3 years, 8 of the 63 women in the surveillance group developed BC, whereas none of the 76 women in the prophylactic-mastectomy group developed BC. However, in their updated paper, 18 only one previously unaffected woman developed metastatic BC almost 4 years after prophylactic mastectomy. Rebbeck et al. 7 evaluated 483 women with deleterious BRCA1 and BRCA2 mutations from the time of their ascertainment to time of surgery. BC was diagnosed in only 1.9 % of women who had BPM, and 49 % of women who did not have the procedure. Hartmann et al. 21 identified 26 women with an alteration in the BRCA1 or BRCA2 genes (18 had deleterious changes, and 8 had variants of uncertain clinical significance) who underwent prophylactic mastectomy. Of these women (26 patients) none developed BC after 13.4 years of follow-up. These studies provide a plethora of evidence for the effectiveness of BPM in BC risk reduction among BRCA mutation carriers.
Our data show a substantial proportion (25 %) of patients who tested negative for a BRCA mutation still elected CPM. Our results confirm that the presence of family history of OC and younger age (B45) at diagnosis explain why these patients elected CPM despite their negative BRCA genetic test result. Few studies examined CPM among patients who tested negative for BRCA mutations; therefore, we are currently analyzing a prospective cohort. Howard-McNatt et al. 22 examined CPM among patients with invasive BC who tested negative for a BRCA mutation. Among 110 women who received genetic testing, 37 % of the BRCA-negative women chose CPM.
Goldflam et al. 23 found evidence that a family history of BC was mostly associated with CPM. They retrospectively reviewed data for 239 patients with unilateral early-stage BC who elected to undergo CPM, and a family history of BC was the most frequent reason given to undergo CPM in more than half of the patients. Contrary to this study, a family history of BC did not predict CPM in our study. However, a family history of OC was not evaluated in the Goldflam study. It has been shown that a family history of OC is more suggestive of a BRCA mutation than a family history of BC. 1 In turn, BRCA positivity is associated with increased risk for primary BC and CBC, which explains why patients are concerned about the risk for CBC and therefore elect CPM. Our data indicated a relationship between BRCA positivity and a family history of OC in CPM predictions.
It is noteworthy to mention the improvements in cosmetic outcomes related to skin and nipple-sparing mastectomy, and expertise in plastic surgical reconstruction, has markedly influenced the use of CPM in patients with DCIS at MD Anderson. In our most recent overall experience among 2,037 patients treated for DCIS, the median pathologic size of the lesion was 1.3 cm, and the use of CPM was highly significantly related to age (37 %, \40 years; 17 %, 40-70 years; 6 % [70 years) as well as the use of immediate reconstruction (82 %, \40 years; 66 %, 40-70 years; 16 %, [70 years). 24 Our results should be interpreted in light of study limitations; this was a retrospective review of clinical data from women who were referred to clinical cancer genetics for genetic counseling and thus a selected population.
Our results may not be generalizable to all patients with DCIS owing to selection bias. Future studies are needed to evaluate patients' perceptions of CBC and how these perceptions affect their decision to undergo CPM. The decision to undergo CPM is personal and individualized; consequently, patients need to have an accurate estimate of their CBC risk as well as potential risks and benefits of CPM. Montgomery and colleagues reported that 6 % of patients who elected CPM regretted their decision for various reasons, such as diminished sense of sexuality, poor cosmetic result, and lack of education regarding alternative methods. 25 Researchers need to explore whether the decision to undergo CPM is driven by physician recommendation or by a complete understanding of CBC risk. Considering the complexity of the decision to undergo CPM, genetic testing is a critical step that, if taken, can help patients interpret their risk and make informed decisions. New data may inform clinicians' recommendations and patients' decision making in weighing CBC risk against the short-and long-term effects of prophylactic surgery. At present, CPM remains a highly desirable procedure among patients with DCIS who wish to reduce their CBC risk.
